Next-generation Immunotherapies for Cancer
Our laboratory focuses on the study of the mechanisms of relapse after chimeric antigen receptor T cell (CART) immunotherapy with the goal of rationally design innovative next-generation immunotherapies for relapsing/refractory leukemia and lymphoma.
For more information, please visit the links below.
If you would like to make a monetary contribution, please see the link below. Thank you in advance for your support!
Select "Special Reason" and leave a note: “Donation to fund Dr. Marco Ruella’s research.